3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
9
INDUSTRY
5
NIH
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
21
Lymphoma
10
Lymphoma, Mantle-Cell
4
Waldenstrom Macroglobulinemia
2
Recurrence
2
Mesothelioma, Malignant
2
Lymphoma, Follicular
2
Stomach Neoplasms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Immunoglobulin Light-chain Amyloidosis
1
Hematologic Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
2
Methods
2
Educational Status
2
Early Intervention, Educational
2
trihexyltetradecylphosphonium chloride
1
letermovir
1
gamma-Globulins
1
Voriconazole
1
Vincristine
1
Vaccination
1
Sirolimus
1
Prednisone
1
Pharmacogenomic Testing
1
Patient Navigation
1
Organizational Objectives
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Lenalidomide
1
Interviews as Topic
1
Infliximab
1
Immunoglobulins, Intravenous
1
Immunoglobulins
1
Health Promotion
1
Fluconazole
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Caspofungin
1
Carvedilol
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Hematologic Neoplasms
×
Bortezomib
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled